Article Text

other Versions

PDF
Unrepresentative Astrocytoma biopsy sampling is partly overcome by assessment of the MIB-1 labeled growth fraction
  1. Katherine M Sheehan (katherinesheehan{at}hotmail.com)
  1. Department of Pathology, Beaumont Hospital and Royal College of Surgeons in Ireland, Republic of Ireland
    1. Maureen Burke
    1. Department of Clinical Neurological Sciences, Beaumont Hospital, Republic of Ireland
      1. Josephine Heffernan
      1. Department of Clinical Neurological Sciences, Beaumont Hospital, Republic of Ireland
        1. Elaine W Kay
        1. Department of Pathology, Beaumont Hospital and Royal College of Surgeons in Ireland, Republic of Ireland
          1. Francesca M Brett
          1. Department of Clinical Neurological Sciences, Beaumont Hospital, Republic of Ireland
            1. Michael A Farrell
            1. Department of Clinical Neurological Sciences, Beaumont Hospital, Republic of Ireland

              Abstract

              Background: Representative sampling of gliomas at biopsy is essential for correct assignation of histologic grade and subsequent patient management. If sampling is unrepresentative, tissue devoid of mitoses or necrosis may be obtained and result in a falsely low glioma grade.

              Objective: To assess whether the MIB-1 labeling index of glioma tissue cores specifically constructed so as to replicate ‘unrepresentative’ astrocytoma biopsies would predict the real or actual glioma grade.

              Methodology: Tissue microarrays were prepared from 134 samples of low-grade astrocytoma [WHO Grade II] , anaplastic astrocytoma and glioblastoma multiforme. Donor blocks were sampled to avoid mitoses, necrosis and endothelial hyperplasia. Immunohistochemistry was performed using the Ki-67 (MIB-1) proliferation marker and the percentage of MIB-1 positive cells per core was calculated.

              Results: Mean MIB-1 % values for LGA (n=47), AA (n=38) and GBM (n=46) were 0.54 (+/-0.82), 5.68 (+/-6.69) and 7.21 (+/-7.98); ranges 0-3.07; 0–30.08 and 0–29.08 respectively. A MIB-1 % count of >3.07 excludes LGA, but a MIB-1 % count of <3.07 does not exclude GBM or AA.

              Conclusion: In unrepresentative glioma biopsy material, MIB-1 labeling may be used to exclude low-grade astrocytoma, but cannot be used to distinguish between GBM and AA.

              • astrocytoma
              • immunohistochemistry
              • neuropathology
              • tumour grading

              Statistics from Altmetric.com

              Request permissions

              If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.